<span item_type="fundamental" item_id="3f96a1265015bf8a00e2c354284ef361" counter_id="ST/US/PETVW" env="prod"></span><span item_type="announcement" item_id="582795992652711809" env="prod"></span><p>Revenue: As of FY2026 Q2, the actual value is USD 303.28 K.</p><p>EPS: As of FY2026 Q2, the actual value is USD -0.11.</p><p>EBIT: As of FY2026 Q2, the actual value is USD -1.123 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: $303,284 for the three months ended September 30, 2025, compared to $200,720 for the same period in 2024. Revenue for the six months ended September 30, 2025 was $600,784, compared to $324,470 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000149315225023398/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: $3,007,809 for the three months ended September 30, 2025, compared to $2,175,493 for the same period in 2024. Net loss for the six months ended September 30, 2025 was $5,318,846, compared to $4,222,556 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000149315225023398/form10-q.htm"></span></li><li><strong>Operating Loss</strong>: $2,065,367 for the three months ended September 30, 2025, compared to $2,173,040 for the same period in 2024. Operating loss for the six months ended September 30, 2025 was $3,909,684, compared to $4,217,473 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000149315225023398/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $3,828,209 for the six months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000149315225023398/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $4,361,829 for the six months ended September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000149315225023398/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Sales of PrecisePRP™ Products</strong>: $116,382 for the three months ended September 30, 2025, contributing to the increase in revenue.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000149315225023398/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to increase commercialization efforts of Spryng® in the United States through distribution relationships and the use of sales reps, clinical studies, and market awareness to educate and inform key opinion leaders on the benefits of Spryng®.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000149315225023398/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company signed an exclusive licensing agreement with VetStem, Inc. to market and sell PrecisePRP™ products for both canine and equine, with revenues expected in fiscal year 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000149315225023398/form10-q.htm"></span></li></ul><h3>Priority</h3><ul><li>The company emphasizes strategies with concrete projections, such as the expected revenue from the VetStem agreement and the expansion of distribution channels for Spryng®.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1512922/000149315225023398/form10-q.htm"></span></li></ul>

PETVIVO HLDGS INC C/WTS 13/08/2026 (TO PUR COM) | 10-Q: FY2026 Q2 Revenue: USD 303.28 K